Chinese expert consensus on the clinical management of liver disease-associated thrombocytopenia syndrome.
10.3760/cma.j.cn501113-20230925-00120
- Collective Name:National Clinical Research Center for Infectious Diseases;;Society of Hepatology, Beijing Medical Association;;Translational Medicine Branch, Chinese Association of Gerontology and Geriatrics
- Publication Type:Journal Article
- Keywords:
Consensus;
Liver disease;
Thrombocytopenia
- MeSH:
Humans;
Consensus;
Thrombocytopenia/complications*;
Liver Diseases/complications*;
Hemorrhage/etiology*;
Blood Platelets
- From:
Chinese Journal of Hepatology
2023;31(11):1137-1148
- CountryChina
- Language:Chinese
-
Abstract:
Liver disease-associated thrombocytopenia syndrome refers to thrombocytopenia caused by liver disease or the treatment of liver disease, and its incidence rate is related to the duration and severity of liver disease. The direct effect of thrombocytopenia on clinical outcomes is an increased risk of bleeding in patients with liver disease, whereas the indirect effect involves delay or termination of treatment due to the potential risk of bleeding. Liver disease-associated thrombocytopenia pathophysiological mechanisms involve decreased platelet production, abnormal distribution, destruction, or increased consumption. Presently, treatment strategies targeting different mechanisms include platelet-stimulating drugs, surgery, immunosuppressive drugs, and platelet transfusion, but the clinical application needs to be standardized further. The National Clinical Research Center for Infectious Diseases organized experts to discuss and formulate consensus with reference to the latest evidence-based medical evidence in the field so as to improve the clinical management level of liver disease-associated thrombocytopenia syndrome in China in terms of diagnosis, typing, and reasonable selection of treatment schemes.
